Ivermectin doesn't meaningfully aid COVID-19 recovery, study finds
Ivermectin, a drug used to treat parasitic infections, has no meaningful benefit for treating COVID-19 symptoms, according to a new study from Duke University.
- Duke and Vanderbilt University researchers studied around 1,500 people with COVID-19, with half receiving ivermectin and the other a placebo.
- The findings were published online Sunday, but have not yet been peer reviewed.
Why it matters: The Duke study is one of the largest clinical trials to show ivermectin — which soared in popularity to treat COVID symptoms during the pandemic — is not effective for doing so.
What they're saying: "Given these results, there does not appear to be a role for ivermectin outside of a clinical trial setting, especially considering other available options with proven reduction in hospitalizations and death," Adrian Hernandez, the executive director of the Duke Clinical Research Institute, said in a statement. Hernandez led the study.
The big picture: This was not the first study to suggest the ineffectiveness of ivermectin against COVID-19.
- A recent study published in the New England Journal of Medicine found the drug does not reduce the risk of COVID-19 hospitalization, Axios reported.
What's next: Duke plans to study ivermectin further, with another volunteer group receiving 50% more of the drug than it did in this study.
Go deeper: Read the full study here.
More Raleigh stories
No stories could be found
Get a free daily digest of the most important news in your backyard with Axios Raleigh.